119 related articles for article (PubMed ID: 25778107)
1. Thyroid function abnormalities associated with ponatinib therapy in patients with chronic myeloid leukemia.
Palani R; Apperley JF; Reid A; Foroni L; Deplano S; Milojkovic D
Thyroid; 2015 Jun; 25(6):706-7. PubMed ID: 25778107
[No Abstract] [Full Text] [Related]
2. The current status of ponatinib in the treatment of chronic myeloid leukemia.
Deininger M
Clin Adv Hematol Oncol; 2014 May; 12(5):329-31. PubMed ID: 25003490
[No Abstract] [Full Text] [Related]
3. BCR-ABL-positive acute myeloid leukemia: About one case treated with ponatinib.
Maël H; Audrey B; Evelyne CB; Pierre-Yves D; Kaddour C; Gilles S; Arnaud P
Ann Hematol; 2017 Feb; 96(2):335-336. PubMed ID: 27761606
[No Abstract] [Full Text] [Related]
4. Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.
Shah NP
Clin Adv Hematol Oncol; 2011 Dec; 9(12):925-6. PubMed ID: 22252660
[No Abstract] [Full Text] [Related]
5. Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts.
Jain P; Romo CG; Khoury HJ; Kantarjian H; Cortes J
Haematologica; 2013 Nov; 98(11):e141-2. PubMed ID: 24186316
[No Abstract] [Full Text] [Related]
6. Ponatinib (Iclusig) for CML and Ph+ ALL.
Med Lett Drugs Ther; 2013 Sep; 55(1424):71-2. PubMed ID: 25970013
[No Abstract] [Full Text] [Related]
7. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
8. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
9. Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation.
Shomali W; Redmond C; Bogati S; Zimmerman C; Visconte V; Tabarroki A; Kalaycio M; Tiu RV
Leuk Lymphoma; 2016; 57(1):193-5. PubMed ID: 25942382
[No Abstract] [Full Text] [Related]
10. The accelerated approval of oncologic drugs: lessons from ponatinib.
Prasad V; Mailankody S
JAMA; 2014 Jan 22-29; 311(4):353-4. PubMed ID: 24449310
[No Abstract] [Full Text] [Related]
11. Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.
Frankfurt O; Licht JD
Clin Cancer Res; 2013 Nov; 19(21):5828-34. PubMed ID: 23935038
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of dasatinib against ponatinib-resistant chronic myeloid leukemia cells.
Okabe S; Tanaka Y; Moriyama M; Gotoh A
Leuk Lymphoma; 2020 Jan; 61(1):237-239. PubMed ID: 31502898
[No Abstract] [Full Text] [Related]
13. Ichthyosiform Reaction Related to Ponatinib Therapy.
Fernández-González P; Buendía-Castaño D; Saceda-Corralo D; Jaen-Olasolo P
Actas Dermosifiliogr (Engl Ed); 2019 Dec; 110(10):873-875. PubMed ID: 31493826
[No Abstract] [Full Text] [Related]
14. Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study.
Caocci G; Mulas O; Capodanno I; Abruzzese E; Iurlo A; Luciano L; Albano F; Annunziata M; Tiribelli M; Bonifacio M; Galimberti S; Castagnetti F; Sgherza N; Stagno F; Gozzini A; Orlandi EM; Luzi D; Binotto G; Pregno P; Fozza C; Efficace F; Simula MP; Trawinska MM; Cattaneo D; De Gregorio F; Attolico I; Stella R; Scaffidi L; Baratè C; Gugliotta G; Scalzulli E; Elena C; Pirillo F; Foà R; Breccia M; Nasa G
Blood Cancer J; 2020 Jun; 10(6):66. PubMed ID: 32514110
[No Abstract] [Full Text] [Related]
15. Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity.
Boo YL; Liam CCK; Toh SG; Lim SM
Hong Kong Med J; 2019 Apr; 25(2):162-163. PubMed ID: 30971509
[No Abstract] [Full Text] [Related]
16. [Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia?].
Thomas X
Bull Cancer; 2011 Jul; 98(7):761-7. PubMed ID: 21700550
[TBL] [Abstract][Full Text] [Related]
17. Ponatinib Exerts an Inhibitory Effect on Collagen-induced Platelet Aggregation and Generation of Coated-Platelets.
Mezei G; Batár P; Kozma L; Illés Á; Kappelmayer J; Debreceni IB
Anticancer Res; 2021 Oct; 41(10):4867-4874. PubMed ID: 34593434
[TBL] [Abstract][Full Text] [Related]
18. Ponatinib in Philadelphia chromosome-positive leukemias.
Quintas-Cardama A
N Engl J Med; 2014 Feb; 370(6):577. PubMed ID: 24499222
[No Abstract] [Full Text] [Related]
19. Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors.
Santoro M; Accurso V; Mancuso S; Contrino AD; Sardo M; Novo G; Di Piazza F; Perez A; Russo A; Siragusa S
Chemotherapy; 2019; 64(4):205-209. PubMed ID: 31825920
[TBL] [Abstract][Full Text] [Related]
20. Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion.
Breccia M; Pregno P; Spallarossa P; Arboscello E; Ciceri F; Giorgi M; Grossi A; Mallardo M; Nodari S; Ottolini S; Sala C; Tortorella G; Rosti G; Pane F; Minotti G; Baccarani M
Ann Hematol; 2017 Apr; 96(4):549-558. PubMed ID: 27686083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]